中国药房2016，Vol.27Issue(34)：4842-4844,3.DOI:10.6039/j.issn.1001-0408.2016.34.28
水飞蓟素肠溶聚乳酸-羟基乙酸共聚物纳米粒的制备及体外释药研究
Preparation and in vitro Drug Release of Enteric-coated Silymarin-PLGA Nanoparticles
摘要
Abstract
OBJECTIVE:To prepare enteric-coated silymarin-PLGA nanoparticles,and to study its in vitro release behavior. METHODS:Using HPMCP as enteric-coated material, nanoprecipitation method was used to prepare enteric-coated silyma-rin-PLGA nanoparticles and silymarin-PLGA nanoparticles. The morphology of nanoparticles were observed,and the particle size, Zeta-potential,encapsulation efficiency,drug-loading amount,stability and in vitro release rate (Q) were detected. The ratio of PLGA-HPMCP in enteric-coated silymarin-PLGA nanoparticles was screened by using particle size, encapsulation ratio and drug-loading capacity as indexes. RESULTS:The best PLGA-HPMCP ratio was 1∶0.25. The particle size of enteric-coated silyma-rin-PLGA nanoparticles and silymarin-PLGA nanoparticles were 224 nm and 193 nm,Zeta potential were -37.8 mV and -40.7 mV;encapsulation ratio were (74.7 ± 2.2)% and (71.7 ± 2.5)%,and drug-loading amount were (5.39 ± 0.24)% and (5.21 ± 0.22)%;the percolation rates of them were 0.2% and 0.5% at 4 ℃ 3 months later;Q48 h of them in simulated gastric fluid were 38.6% and 70.5%,and Q48 h of them in simulated intestinal fluid were 80.2% and 73.5%,respectively. CONCLUSIONS:The en-teric-coated silymarin-PLGA nanoparticles are prepared successfully with good stability,and can effectively inhibit the release of si-lymarin in simulated gastric fluid.关键词
水飞蓟素/聚乳酸-羟基乙酸共聚物/羟丙基甲基纤维素邻苯二甲酸酯/纳米粒/体外释放度Key words
Silymarin/PLGA/HPMCP/Nanoparticle/Release rate in vitro分类
医药卫生引用本文复制引用
何静,邱妍川,杨延音,刘松青,林凤云,江尚飞,朱照静..水飞蓟素肠溶聚乳酸-羟基乙酸共聚物纳米粒的制备及体外释药研究[J].中国药房,2016,27(34):4842-4844,3.基金项目
重庆市科技攻关计划项目（No.cstc2012gg-yyjs 10008）；重庆市卫生局医学科研计划项目 （）
